Who are FULVESTRANT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inluriyo, Orserdu, Faslodex, Abemaciclib + Fulvestrant, Tamoxifen, Letrozole, Anastrozole or Exemestane, E2 patch/antagonist.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl1358.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FULVESTRANT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FULVESTRANT (FULVESTRANT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen Receptor Antagonist [EPC].

marketed Estrogen Receptor Antagonist [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

FULVESTRANT (FULVESTRANT).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FULVESTRANT TARGET	FULVESTRANT		marketed	Estrogen Receptor Antagonist [EPC]		2002-01-01
Inluriyo	IMLUNESTRANT	Eli Lilly And Co	marketed	Estrogen Receptor Antagonist [EPC]		2025-01-01
Orserdu	ELACESTRANT	Stemline Therap	marketed	Estrogen Receptor Antagonist [EPC]	Estrogen receptor	2023-01-01
Faslodex	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
Abemaciclib + Fulvestrant	Abemaciclib + Fulvestrant	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + estrogen receptor antagonist	CDK4/6 and estrogen receptor (ER)
Tamoxifen, Letrozole, Anastrozole or Exemestane	Tamoxifen, Letrozole, Anastrozole or Exemestane	Institut Claudius Regaud	marketed	Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane)	Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane)
E2 patch/antagonist	E2 patch/antagonist	Weill Medical College of Cornell University	marketed	Estrogen receptor antagonist / hormone replacement therapy	Estrogen receptor (ER-α, ER-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US

Sponsor landscape (Estrogen Receptor Antagonist [EPC] class)

· 1 drug in this class
AstraZeneca · 1 drug in this class
Eli Lilly And Co · 1 drug in this class
Stemline Therap · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FULVESTRANT — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1358. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing